MedTrace Logo

PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases

NCT02084147 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2019-10-29

Study results available
· View outcomes & findings →

Summary

This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac diseases, or neurologic diseases. PET-MRI combines two imaging methods that can be used to evaluate disease. PET-MRI is similar to standard-of-care PET-CT, but exposes the patient to less radiation. It is not yet known whether PET-MRI produces better image quality than PET-CT in diagnosing patients with cancer, cardiac disease, or neurologic disease.

Conditions

  • Cardiac Disease
  • Dementia
  • Inflammatory Disease
  • Fever of Unknown Origin
  • Vasculitis
  • Osteomyelitis
  • FDG Avid Cancers

Interventions

DEVICE

positron emission tomography

Undergo PET

DEVICE

computed tomography

Undergo CT

DEVICE

magnetic resonance imaging

Undergo MRI

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Pablo Ros, MD, MPH, PhD · Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-07
Primary Completion
2016-09-14
Completion
2018-10-02
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084147 on ClinicalTrials.gov